VCNX: Vaccinex, Inc Net earnings per share (EPS TTM)

Vaccinex (VCNX) - corporate logo

Vaccinex, Inc. (VCNX) possesses robust R&D potential driven by its pepinemab platform for cancer treatment. The TTM net income per share reflects profit dynamics, where a metric value of 7.44 serves as an indicator of resilience. US-based operations are shielded from trade conflicts, while production outsourcing allows the team to maintain flexibility without incurring unnecessary costs.

VCNX Vaccinex, Inc. Net earnings per share for the last 12 months (07/04/2022 - 12/28/2024)

Summary analytical data breakdowns for Vaccinex Inc (VCNX)

- share price and expert price forecast:
Stock Quotes Vaccinex|VCNX - Fair Value Consensus
- market capitalization information:
Market Capitalization Vaccinex|VCNX - Company Buyout Price
- business book valuation details:
Net Assets per Single Share Vaccinex|VCNX - Company Net Assets|Market Value to Book Value Ratio vaccinex.com|VCNX - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Vaccinex, Inc.|VCNX - Long-Term Debt to Capital|Short-Term Debt to Equity Vaccinex|VCNX - Company Aggregate Debt|Debt to Book Capitalization Ratio Vaccinex, Inc.|VCNX - Long-Term Debt|Company Current Liabilities Vaccinex|Quick Liquidity Indicator vaccinex.com
- earnings and multiples data:
VCNX - Profit After Payment of Taxes|Projected Future Earnings Vaccinex, Inc.|VCNX - Company Value to Net Income|Forward P/E Multiple vaccinex.com|VCNX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Vaccinex Inc|VCNX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Vaccinex|VCNX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months vaccinex.com|VCNX - Earnings per share trend in current year|Expected earnings per share growth for next year Vaccinex, Inc.
- revenue and sales details:
VCNX - Company Total Revenue|Company Future Sales Volume Vaccinex|VCNX - Price-to-Revenue Ratio|Forward P/S Multiple Vaccinex Inc.
Fundamental valuation:VCNX - Vaccinex Inc
Flagship merchandise of Vaccinex, Inc

Net income per share for Vaccinex, Inc. (VCNX) is calculated as the ratio of total annual income to the total number of securities. This indicator filters out market noise, demonstrating real profitability trends without the influence of one-off transactions. The current value of 7.44 reflects financial pressure caused by costs associated with cancer therapy clinical trials. Risks regarding the prolongation of contracts with pharma behemoths make the 12-month rolling EPS a critical marker of stability. Analyzing this trend helps avoid investing in an asset with depleting capital.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Immatics Corp IMTX|Xencor Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|LYEL (lyell.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)